CAMBRIDGE, Mass., April 27, 2017 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) and Aurigene Discovery Technologies Limited today announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target.
Under the terms of the agreement, Aurigene will provide Agios exclusive rights to its portfolio of novel small molecules for the undisclosed target. Financial terms of the agreement include a $3 million upfront payment and potential future milestone payments of up to $17 million per licensed product if certain development and regulatory milestones are achieved by Agios. Aurigene is also eligible to receive low single-digit royalties on product sales. Agios will conduct preclinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit the company’s website at www.agios.com.
Aurigene is a specialized biotechnology company, engaged in discovery and early clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene is focused on oral check-point inhibitors, precision-oncology and the Th-17 pathway. Aurigene’s oral PD-L1/ VISTA antagonist program is currently in Phase 1 clinical development with its partner. Aurigene has partnered with several large- and mid-pharma companies in the United States and Europe and has delivered over 15 compounds which are in clinical development. Aurigene is an independent, wholly owned subsidiary of Dr. Reddy’s Laboratories Ltd. (NYSE:RDY).
Aurigene a discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases, announced today the nomination of the development candidate and exercising of the option for CA-327, an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and T-cell immunoglobulin and mucin domain containing protein-3 (TIM-3) by Curis, Inc.
CA-327 is the third program in the Aurigene – Curis collaboration signed in January 2015. The first two programs under the collaboration are an orally available small molecule antagonist of programmed death ligand-1 (PD-L1) and V-domain Ig suppressor of T cell activation (VISTA) in the immuno-oncology field, and an orally available, small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 (IRAK4) in the precision oncology field.
In September 2016 the agreement was amended allowing Aurigene to invest upto to 10.2 million shares of Curis’s common stock in lieu of $24.5 million of milestone and other payments.
“We are pleased with the progress of our collaboration,” said Dr. Ali Fattaey, Curis’s CEO, “and look forward to working with our partner, Aurigene, to complete IND-enabling studies for CA-327 in the coming months and expect to file an IND in 2017.”
“We are delighted that our collaboration is advancing its third small molecule program in less than two years,” said CSN Murthy, Aurigene’s CEO. “We continue to work closely with Curis to focus our collective resources, creating and developing innovative drug candidates in the field of oncology, including multiple first-in-class oral small molecule checkpoint antagonists within immuno-oncology. For Aurigene, this demonstrates the validation of its platform technology in the development of oral checkpoint inhibitors, with the second program (PD-L1/ TIM3) rapidly advancing to candidate nomination status after the PD-L1/ VISTA program. This allows us to confidently make progress on other checkpoint targets in the I/O space in the coming months and years”.
Aurigene is a discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene’s PD-L1/Vista small molecule program that is currently being investigated in a Phase 1 trial in patients, is the first of several immune checkpoint programs at different stages of discovery and preclinical development. Aurigene has signed four licensing deals for multiple programs in the last three years, covering immune-oncology and epigenetic pathway programs. Of these, one program is in Phase 1 clinical development, IND/ CTA has been filed for a second program, and two programs are currently in IND-enabling pre-clinical studies. Among others, Aurigene has advanced stage assets targeting: (a) RORg for autoimmune diseases in IND enabling studies (b) Novel NAMPT inhibitors for oncology, in preclinical development, (c) Covalent CDK7 inhibitors for oncology, in late lead optimization stage, and (d) Covalent and G12C selective KRAS small molecule inhibitors in preclinical development.
About the Curis Collaboration
On January, 2015, Aurigene entered into collaboration, license and option agreement focussed on immuno-oncology and selected precision oncology targets with Curis, Inc., a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers.
The agreement provides Curis the option to license-in programs when a development candidate is nominated. The first two licensed programs under the collaboration are an orally available small molecule antagonist of PD-L1/ VISTA in the immuno-oncology field, and an orally available, small molecule inhibitor of IRAK4 in the precision oncology field. With the licensing of CA-327, a third licensed program has been added to the portfolio of compounds under development by Curis.
In partial consideration for the rights granted to Curis under the collaboration agreement, Curis issued about 17.1 million shares of common stock to Aurigene, and additional development and regulatory milestones of over $ 200 million, apart from commercialization rights for the programs in India and Russia, sharing of value in non-US/ EU makets with Aurigene, Drug Substance and Drug Product manufacturing rights and royalties on net sales ranging between high single digits to 10%
In September 2016, the Agreement between the partners was amended allowing Aurigene to invest upto to 10.2 million shares of Curis’s common stock in lieu of $24.5 million of milestone and other payments.
Director Corporate Development & Strategy
+91 – 40 – 4465 7777
2017-02-06T18:31:12+00:00 October 11th, 2016|
By Vikas Dandekar, ET Bureau | Jul 01, 2016, 03.44 AM IST
MUMBAI: Aurigene Discovery Technologies has moved one step closer to developing a capsule that can potentially alter the treatment paradigm from painful intravenous injections currently used to treat advanced form of cancers such as melanoma, lung cancer and advanced renal cell carcinoma. The Bengaluru-based company is an independent subsidiary of Dr Reddy’s Laboratories and its United States-based partner Curis Inc.
The two partners recently announced the dosing of the first patient as part of a phase one clinical trial for the drug coded CA-170, which has been described by industry watchers as a breakthrough and first such candidate in the world in a fiercely competed set of experimental drugs called checkpoint inhibitors.
Checkpoint inhibitors or the mechanism of blocking proteins that are expressed on cancer cells or immune cells in the human body and trigger the body’s immune system to fight cancer cells is the latest frontier in cancer research with large drug makers pumping in billions of dollars in search of effective leads.
For Curis Inc and Aurgiene Discovery Technologies, the journey is likely to be long and tedious, with associated risks of failure in clinical development cycle, and could take four to six years to reach a stage of commercialisation. But if all goes well, a bounty awaits, experts said. The two marketed intravenous drugs Keytruda (pembrolizumab) of Merck and Opdivo (nivolumab) from Bristol Myers Squibb clocked about $1.5 billion or Rs 10,000 crore in sales in 2015.
The industry expects the expanding field of immune-oncology drugs including blockers of immune checkpoints such as CTLA4, PD-1, Vista, TIM3 and others to top $35 billion in revenue in the next eight years. Aurigene Discovery Technologies CEO CSN Murthy told ET, “The success of this (CA-170) programme will pave the way for a number of other oral immune checkpoint inhibitors in the pipeline at Aurigene, including a dual PD-L1/TIM3 inhibitor also licensed to the same partner – Curis Inc. Aurigene’s platform technology will see multiple opportunities develop over the next couple of years.”
According to the company’s researchers, CA-170, a dual PD-L1/Vista inhibitor agent, has many firsts to its credit. The ability to simultaneously block two important immune checkpoints, PD-L1and Vista, can potentially address certain patients who show resistance to existing therapies, they said.
By being the only oral capsule in development, the drug adds to the convenience and compliance of patients. As a small molecule (in contrast to the existing checkpoint inhibitors that are large proteins), the potential for CA-170 to penetrate cancer tissues is much higher. Additionally, CA-170 provides added flexibility to combine with other anti-cancer agents to provide better safety profile, especially in cases of immune related adverse events.
Aurigene will present data on its potent and selective CDK7 novel covalent inhibitor program and KRAS covalent inhibitor targeting G12C mutations – Both of these programs are currently in Lead Optimization.
Additional information on the presentations can be found below and abstracts can be accessed at www.aacr.org.
KRAS G12C Covalent Inhibitors
Title: Identification of novel covalent inhibitors of KRAS G12C that are efficacious in a xenograft model of NSCLC
Session ID: Poster Section 17
Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Antitumor Agents
Session Date and Time: Sunday Apr 17, 2016 1:00 PM – 5:00 PM
Location: Convention Center, Halls G-J, Poster Section 17
Permanent Abstract Number: 339
Selective CDK7 Covalent Inhibitors
Title: Potent and selective inhibition of CDK7 by novel covalent inhibitors
Session ID: Poster Section 19
Session Category: Experimental and Molecular Therapeutics
Session Title: Small Molecule Inhibitors
Session Date and Time: Tuesday Apr 19, 2016 8:00 AM – 12:00 PM
Location: Convention Center, Halls G-J, Poster Section 19
Permanent Abstract Number: 3070
Aurigene is a specialized, discovery stage biotechnology company, developing novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene’s Programmed Death pathway program is the first of several immune checkpoint programs that are at different stages of discovery and preclinical development. Aurigene has signed four licensing deals in the last couple of years. Aurigene is currently seeking partners for its current pipeline of advanced assets (a) RORg for autoimmune diseases which is in preclinical development (b) Novel NAMPT inhibitors for niche cancers, also in preclinical development (c) Covalent CDK7 and KRAS small molecule programs that are currently in lead optimization. For more information about Aurigene and our pipeline, please visit Aurigene’s website at http://aurigene.com/